Hyderabad News Desk

DelveInsight’s, “Nonalcoholic Steatohepatitis Pipeline Insight” report provides comprehensive insights about 100+ Nonalcoholic Steatohepatitis companies and 150+ pipeline drugs in the Nonalcoholic Steatohepatitis pipeline landscape. It covers the Nonalcoholic Steatohepatitis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Nonalcoholic Steatohepatitis Pipeline Report

• DelveInsight’s Nonalcoholic Steatohepatitis pipeline report depicts a robust space with 100+ active players working to develop 150+ pipeline therapies for Nonalcoholic Steatohepatitis treatment.
• The leading Nonalcoholic Steatohepatitis Companies working in the market include Madrigal Pharmaceuticals, Cirius Therapeutics, AstraZeneca, Ionis Pharmaceuticals, NorthSea Therapeutics, Rivus Pharmaceuticals, Akero Therapeutics, Merck Sharp & Dohme LLC, Enanta Pharmaceuticals, Taiwan J Pharmaceuticals, Cascade Pharmaceuticals, Hepion Pharmaceuticals, Chipscreen Biosciences, Boston Pharmaceuticals, Bristol-Myers Squibb, GSK plc., Amgen, Altimmune Inc., Sciwind Biosciences, SCOHIAPHARMA, Galecto Biotech, J2H Biotech, Tiziana Life Sciences, Palobiofarma, BirdRockBio, Ascletis, Liminal BioSciences, ARTham Therapeutics, Pliant Therapeutics, Guangdong Zhongsheng Pharmaceutical, Pharmaxis, Melior Pharmaceuticals, TransThera Biosciences, Cerenis Therapeutics, DURECT Corporation, Enzychem Lifesciences, Ildong Pharmaceutical, LG Chem Lifesciences, Gmax Biopharm, Albireo Pharma, Inorbit TX, Viking Therapeutics, Thoth Science, and others.
• Promising Nonalcoholic Steatohepatitis Pipeline therapies in the various stages of development include Semaglutide (SEMA), Cilofexor (CILO)/Firsocostat (FIR), EDP-305 Dose 1, AZD2693, and others.
• January 2024: Novo Nordisk A/S announced a study of Phase 2 clinical trials for NNC0194 0499 50 mg/mL and Semaglutide 3 mg/mL. This study is being done to see if a combination of 2 medicines (called NNC0194-0499 and semaglutide) can reduce liver damage in patients with non-alcoholic steatohepatitis (NASH).
• January 2024: AstraZeneca announced a study of Phase 2 clinical trials for AZD2693. A Study to Evaluate the Efficacy, Safety and Tolerability of AZD2693 given by subcutaneous injection in adult participants with non-cirrhotic non-alcoholic steatohepatitis with fibrosis and who are carriers of the PNPLA3 148M Risk Allele.
• January 2024: Zydus Therapeutics Inc. announced a study of Phase 2 clinical trials for Saroglitazar Magnesium 2mg. This is a randomized, double-blind, placebo-controlled study to evaluate safety and efficacy of Saroglitazar Magnesium 2 mg and 4 mg in patients with NASH. This study will be initiated after obtaining the approvals of Institutional Ethics Committee/Institutional Review Board (IEC/IRB) and the local regulatory authority.
• January 2024: Genentech Inc. announced a study of Phase 2 clinical trials for BFKB8488A. This study will evaluate the efficacy, safety, and pharmacokinetics of BFKB8488A compared to placebo in participants with non-alcoholic steatohepatitis (NASH).

Request a sample and discover the recent advances in Nonalcoholic Steatohepatitis Drugs @ Nonalcoholic Steatohepatitis Pipeline Outlook Report

In the Nonalcoholic Steatohepatitis Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, Nonalcoholic Steatohepatitis clinical trials studies, NDA approvals (if any), and product development activities comprising the technology, Nonalcoholic Steatohepatitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details. The assessment part of the report embraces, in depth Nonalcoholic Steatohepatitis commercial assessment and clinical assessment of the Glioma pipeline products under development.

Nonalcoholic Steatohepatitis Overview

Nonalcoholic steatohepatitis (NASH) is liver inflammation and damage caused by a fat buildup in the liver. It is part of a group of conditions called nonalcoholic fatty liver disease. Nonalcoholic fatty liver disease can be divided into the isolated fatty liver in which there is only accumulation of fat, and nonalcoholic steatohepatitis (NASH), in which there is fat, inflammation, and damage to liver cells. In NASH, there is an abnormal amount of fat in the liver cells, but, in addition, in NASH, there is inflammation within the liver, and, as a result, the liver cells are damaged, they die, and are replaced by scar tissue.

Find out more about Nonalcoholic Steatohepatitis Analysis @ Nonalcoholic Steatohepatitis Drugs

Nonalcoholic Steatohepatitis Emerging Drugs Profile

• Resmetirom: Madrigal Pharmaceuticals
• MSDC-0602K: Cirius Therapeutics
• ION224: Ionis Pharmaceuticals
• HU 6: Rivus Pharmaceuticals
• HTD 1801: HighTide Biopharma
• EDP-305: Enanta Pharmaceuticals

Nonalcoholic Steatohepatitis Therapeutics Assessment

There are approx. 130+ Nonalcoholic Steatohepatitis companies which are developing the Nonalcoholic Steatohepatitis therapies. The Nonalcoholic Steatohepatitis companies which have their drug candidates in the most advanced stage, i.e. phase III include, Madrigal Pharmaceuticals.

Nonalcoholic Steatohepatitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Dive deep into rich insights for new Nonalcoholic Steatohepatitis, visit @ Nonalcoholic Steatohepatitis Treatment Landscape

Nonalcoholic Steatohepatitis Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Scope of the Nonalcoholic Steatohepatitis Pipeline Report

• Coverage- Global
• Nonalcoholic Steatohepatitis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Nonalcoholic Steatohepatitis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Nonalcoholic Steatohepatitis Companies- Madrigal Pharmaceuticals, Cirius Therapeutics, AstraZeneca, Ionis Pharmaceuticals, NorthSea Therapeutics, Rivus Pharmaceuticals, Akero Therapeutics, Merck Sharp & Dohme LLC, Enanta Pharmaceuticals, Taiwan J Pharmaceuticals, Cascade Pharmaceuticals, Hepion Pharmaceuticals, Chipscreen Biosciences, Boston Pharmaceuticals, Bristol-Myers Squibb, GSK plc., Amgen, Altimmune Inc., Sciwind Biosciences, SCOHIAPHARMA, Galecto Biotech, J2H Biotech, Tiziana Life Sciences, Palobiofarma, BirdRockBio, Ascletis, Liminal BioSciences, ARTham Therapeutics, Pliant Therapeutics, Guangdong Zhongsheng Pharmaceutical, Pharmaxis, Melior Pharmaceuticals, TransThera Biosciences, Cerenis Therapeutics, DURECT Corporation, Enzychem Lifesciences, Ildong Pharmaceutical, LG Chem Lifesciences, Gmax Biopharm, Albireo Pharma, Inorbit TX, Viking Therapeutics, Thoth Science, and others.
• Nonalcoholic Steatohepatitis Pipeline therapies- Semaglutide (SEMA), Cilofexor (CILO)/Firsocostat (FIR), EDP-305 Dose 1, AZD2693, and others.

For further information on the Nonalcoholic Steatohepatitis Pipeline Therapeutics, reach out @ Nonalcoholic Steatohepatitis Therapeutics Segmentation

Table of Content

1. Introduction
2. Executive Summary
3. Nonalcoholic Steatohepatitis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Nonalcoholic Steatohepatitis– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Resmetirom: Madrigal Pharmaceuticals
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. ION224: Ionis Pharmaceuticals
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. AMG 609: Amgen
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name : Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Nonalcoholic Steatohepatitis Key Companies
21. Nonalcoholic Steatohepatitis Key Products
22. Nonalcoholic Steatohepatitis- Unmet Needs
23. Nonalcoholic Steatohepatitis- Market Drivers and Barriers
24. Nonalcoholic Steatohepatitis- Future Perspectives and Conclusion
25. Nonalcoholic Steatohepatitis Analyst Views
26. Nonalcoholic Steatohepatitis Key Companies
27. Appendix

Find out more about Nonalcoholic Steatohepatitis Therapeutics Assessment @ Nonalcoholic Steatohepatitis Preclinical and Discovery Stage Products

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/cystic-fibrosis-market